Search

Search Constraints

You searched for: Author/Creator Else, Laura

Search Results

2. Switching Safely: Pharmacokinetics, Efficacy and Safety of Switching Efavirenz to Maraviroc Twice Daily in Patients on Suppressive Antiretroviral Therapy. Issue 2 (February 2015)

4. Evidence of HIV pre-exposure or post-exposure prophylaxis (PrEP/PEP) among blood donors: a pilot study, England June 2018 to July 2019. (29th March 2021)

5. An Open Label, Adaptive, Phase 1 Trial of High‐Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS‐CoV‐2. Issue 3 (13th November 2021)

6. Removal of doravirine by haemodialysis in people living with HIV with end-stage renal disease. (15th April 2022)

7. 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study. Issue 8 (August 2022)

8. Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. (10th March 2022)

9. Single oral dose of maraviroc does not prevent ex-vivo HIV infection of rectal mucosa in HIV-1 negative human volunteers. (23rd October 2015)

10. Total and Unbound Doravirine Concentrations and Viral Suppression in CSF. (21st September 2021)